ArticleIranian journal of pharmaceutical research : IJPR
Astragalus Polysaccharide Suppresses Inflammation and Promotes Apoptosis in Hypertrophic Scars by Suppressing OGT-Mediated Nrf2 O-GlcNAcylation.
Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypertrophic scars (HS) arise from excessive tissue proliferation during wound healing, with Nrf2 involved, though the underlying mechanism remains unclear. Astragalus polysaccharides (APS) have anti-inflammatory and antioxidant properties, but their therapeutic effects and mechanisms in HS remain unreported. Objectives: This study intends to clarify how APS target protein O-GlcNAcylation to treat HS. Methods: A HS mouse model was established by subcutaneous injection of bleomycin (BLM) in C57BL/6 mice. Histopathology (H&E and Masson staining), ELISA, CCK-8, flow cytometry, western blot, and co-immunoprecipitation were performed to assess pathological changes, cell viability, apoptosis, inflammatory cytokine levels, and protein O-GlcNAcylation. Results: Astragalus polysaccharides treatment significantly inhibited scar formation and reduced inflammatory cytokine levels in HS mice. In human hypertrophic scar fibroblasts (HHSFs), APS suppressed cell viability and inflammation while promoting apoptosis. Mechanistically, APS decreased global O-GlcNAcylation levels and downregulated the protein expression of OGT and Nrf2. Mechanistically, OGT interacted with Nrf2, enhancing its stability via O-GlcNAcylation at S199. Moreover, Nrf2 overexpression reversed APS-induced changes in HHSF viability, inflammation, and apoptosis. Conclusions: This study identifies the OGT-mediated O-GlcNAcylation of Nrf2 as a novel regulatory mechanism in HS progression. By suppressing this axis, APS demonstrates therapeutic potential for HS. These findings highlight O-GlcNAcylation as a promising therapeutic target and support the clinical development of APS for fibrotic skin disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.